Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Hydroxychloroquine now...

    Hydroxychloroquine now a Prescription Drug: Health Ministry gazette puts it in Schedule H1 of DCA

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 27 March 2020 7:37 AM  |  Updated On 27 March 2020 7:40 AM
    Hydroxychloroquine now a Prescription Drug: Health Ministry gazette puts it in Schedule H1 of DCA

    New Delhi: Soon after banning the export of the Drug Hydroxychloroquine in light of the coronavirus, the government has now made the Drug into a prescription one to make sure that there is no panic buying of the drug leading to unnecessary shortages.

    This means that the drug will no longer be available over the counter, and would be only available based on prescriptions.

    Through a recent notification of the Gazette of India, The Ministry of Health and Family Welfare has placed the drug Hydroxychloroquine under prescription drugs in order to to restrict the sale of Drug Hydroxychloroquine which is used for the preparation of COVID-19 antidotes.

    " Whereas, the Central Government is satisfied that the drug 'Hydroxychloroquine' is essential to meet the requirements of emergency arising due to pandemic COVID-19 and in the public interest, it is necessary and expedient to regulate and restrict the sale and distribution of the drug 'Hydroxychloroquine' and preparation based thereon for preventing their misuse, " the gazette notification stated

    "Now, therefore, in the exercise of the powers conferred by Section 26B of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government hereby directs that sale by retail of any preparation containing the drug Hydroxychloroquine shall be in accordance with the conditions for the sale of drugs specified in Schedule H1 to the Drugs and Cosmetics Rules, 1945," the gazette notification added

    This order shall come into force on the date of its publication in the Official Gazette that is 26,th March 2020.

    Medical Dialogues had earlier reported that in order to ensure adequate supply of the drug Hydroxychloroquine which has been approved by the ICMR for prophylactic treatment of COVID-19 in certain cases

    Read also: BAN on export of anti-malarial drug hydroxycloroquine with immediate effect: Govt

    For the full details click on the link mentioned below:

    https://business.medicaldialogues.in/pdf_upload/pdf_upload-125966.pdf


    coronaviruscovid-19hydroxychloroquine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok